Key result
High ARF1 expression was significantly associated with poorer overall survival in patients with epithelial ovarian cancer (HR 3.260).
Observational (n=119)
Hazard Ratio: 3.26 (95% CI 1.814–5.856)
p-value: p=0.001
ARF1 promotes cell proliferation and migration in ovarian cancer via the PI3K pathway, highlighting its potential as a diagnostic and therapeutic target.
Supports ARF1 as a prognostic biomarker in epithelial ovarian cancer; hypothesis-generating and requires prospective validation.
ADP-ribosylation factor 1 (ARF1) is a small G protein that regulates many cellular processes such as reorganization of the actin cytoskeleton and is highly expressed in various tumor cells and tissues. However, the role of ARF1 in ovarian cancer progression remains unknown. In the present study, we explored the expression patterns of ARF1 in clinical ovarian cancer samples and adjacent noncancerous tissues. The results revealed that ARF1 overexpressed in EOC tissues and cell lines, compared with the adjacent non-tumorous tissues and normal ovarian cells. In addition, the immunoreactivity of ARF1 was positively correlated with EOC grade and Ki-67 expression. Knockdown of ARF1 expression notably inhibited cell proliferation and migration rate of EOC cells by the auxiliary of PI3K. Taken together, our findings provide new insights into the functional role of ARF1 on EOC cell growth and migration and it may serve as a diagnostic and therapeutic target.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2017) conducted an observational in Epithelial ovarian cancer (n=119). High ARF1 expression vs. Low ARF1 expression was evaluated on Overall survival (HR 3.260, 95% CI 1.814-5.856, p=0.001). High ARF1 expression was significantly associated with poorer overall survival in patients with epithelial ovarian cancer (HR 3.260).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: